American Society of Hematology. (2017).
FDA Approves Vemurafenib for Erdheim-Chester Disease.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-approves-vemurafenib-for-erdheim-chester-disease.
American Society of Hematology.
"FDA Approves Vemurafenib for Erdheim-Chester Disease." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-approves-vemurafenib-for-erdheim-chester-disease
(label-accessed April 25, 2024).
"American Society of Hematology."
FDA Approves Vemurafenib for Erdheim-Chester Disease, 25 Apr. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-approves-vemurafenib-for-erdheim-chester-disease.
